Navigation Links
InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Date:2/1/2010

n. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail in the risk factors attached as Exhibit 99.3 to InterMune’s Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 8-K and InterMune's other periodic reports filed with the SEC.  InterMune undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in InterMune's expectations.  

SOURCE InterMune, Inc.

RELATED LINKS

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Today, eight groups representing ... biologics – Alliance for Patient Access, American ... Rheumatology, Biologics Prescribers Collaborative, Clinical Immunology Society, ... and North American Society for Pediatric Gastroenterology, ... to U.S. Food and Drug Administration (FDA) ...
(Date:5/21/2015)... CITY and SEATTLE , ... leader in the development of robotics, sensors and medical ... as the company,s Chief Financial Officer and head ... of experience in corporate development, business development and finance ... Intellectual Ventures and Pendrell Corporation.  Mr. Woo will be ...
(Date:5/21/2015)... May 21, 2015 Increasing requirements, including ... made flat gaskets indispensable in the chemical and ... internal pressure pose major challenges to their performance. ... of three different materials whose scope covers the ... The white FG-360, based on DIN 28091-3, ...
Breaking Medicine Technology:Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4Sarcos Corp. Announces Preston Woo as CFO and Head of Corporate Development 2Flat gaskets for especially demanding applications in the processing industry 2
... , CLEVELAND, Dec. 16 ... services company focused on global eClinical solutions for the ... version 9.0 eClinical Software. This release advances the ... introduces two new mechanisms for facilitating DATATRAK ONE,s Knowledge(TM) ...
... , , , , ... at,deCODE genetics, Inc. (Nasdaq: DCGN ) publish in the journal Nature the,discovery ... human genome (SNP) with a major impact on susceptibility to type 2,diabetes ... unusual:,if an individual inherits it from their father, the variant increases risk ...
Cached Medicine Technology:DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4
(Date:5/22/2015)... 22, 2015 In efforts to offer ... section containing particular muscles stretches has been a large ... of stretches now complete, Chunk Fitness envisions a mid-June ... be filmed and released at a later point in ... here: http://www.chunkfitness.com/stretches . , About the Company: Chunk ...
(Date:5/22/2015)... May 22, 2015 Javon Bea ... be recognized for providing the highest quality emergency care ... health care decision-making,” said Javon R. Bea, President and ... commitment of our employee/partners to care for and respond ... Hospitals do not apply for this award, but are ...
(Date:5/22/2015)... Orlando, FL (PRWEB) May 22, 2015 ... United States and developmental projects in rural India. India ... most popular community projects that continues to help hundreds ... is pleased to sponsor a music concert by famous ... fundraise for the Hindu Society of Central Florida ...
(Date:5/21/2015)... May 21, 2015 Her popular Love Seminar ... Hilton Hotel in San Gabriel on Saturday, May 23rd. ... again from men and women who are unhappy in their ... partner." , "Many singles think that their biggest problem is ... would go from one relationship to another trying to find ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 Absolute ... has a highly interactive, state-of-the-art website that is filled ... latest trade show resource information. With its original and ... well as practical. The website shows hundred of pictures ... trade show floor. This is not an exhibit rendering ...
Breaking Medicine News(10 mins):Health News:Mercy Hospital and Trauma Center Receives Women’s Choice Award for Emergency Care - Mercy Health System Javon Bea 2Health News:India Network Visitor Health Insurance Announces Corporate Sponsorship of Anuradha Paudwal Musical in Orlando to Help Fundraise for Hindu Society of Central Florida. 2Health News:Bestselling Author Sheds Light on Why Modern Dating is Hurting People's Chances of Finding a Lasting Relationship 2Health News:New Convention and City Travel Guides Within the Absolute Exhibits’ Website 2
... returned sound to young adults with acoustic neuromas , FRIDAY, ... no longer hear her mother,s voice or the sound of ... earlier, Garrett learned she had neurofibromatosis type 2 (NF2), a ... tumors, acoustic neuromas, damaged the eighth cranial nerve in one ...
... , DETROIT, Sept. 11 United American Healthcare ... its financial results for the fourth fiscal quarter and full year ... close. The Company expects to file its Form 10-K for ... (SEC) on a timely basis in compliance with applicable regulations. ...
... that are now emerging from various clinical trials of ... We expect additional companies to announce their preliminary trial ... that 2009 H1N1 influenza vaccines are well tolerated and ... when administered in a single unadjuvanted 15-microgram dose. We ...
... treatment, researchers say , FRIDAY, Sept. 11 (HealthDay News) ... to develop the most common form of the autoimmune ... it, new research shows. , Lupus, also known ... that often affects the joints, kidneys, blood and nervous ...
... The U.S. Food and Drug Administration today released ... articles can be accessed from the agency,s Web page ... can sign-up for e-mail notices of new consumer updates ... https://service.govdelivery.com/service/subscribe.html?code=USFDA_9 . An RSS feed is also ...
... hard-of-hearing may benefit from electronic assistance, researchers say , ... lips better than people can, new research suggests. , ... the deaf and hard-of-hearing learn to read lips, according ... England. , Researchers compared the accuracy of an automated ...
Cached Medicine News:Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:United American Healthcare Corporation Announces Release Date for Fiscal 2009 Fourth Quarter and Full Year Results 2Health News:Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 2Health News:Lupus Worse in Blacks, Hispanics Than in Whites, Study Finds 2Health News:FDA Consumer Health Information Updates 2Health News:FDA Consumer Health Information Updates 3Health News:Computers Might Make Learning Lip Reading Easier 2
Fine .12mm Tip With 5mm Platform; In Titanium....
45 Degree Angle With 0.3, 12 Teeth with 5mm Tying Platform; In Titanium....
Curved 30mm shaft (in stainless steel); rubber coated for safer use; includes 1.5 meter cable and connectors....
0.3mm tips; 9.5mm from tips to cross action; in Titanium....
Medicine Products: